STTK Shattuck Labs: Price-to-Projected Revenue Ratio
Shattuck Labs, Inc. (STTK) develops breakthrough protein-based therapies to combat tumors via dual immune activation. The forward P/S ratio on GURU.Markets captures valuation dynamics, where the 456.70 mark reflects the current state. The model relies on external CRO contractors for testing, minimizing manufacturing plant expenditures. Development risks are mitigated by a liquidity reserve and a broad spectrum of researched cancer types.
Analytical breakdowns for shattucklabs.com (STTK)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company liabilities and liquidity data:
- financial results and valuation multiples details:
STTK - Net Profit|Future Profit Shattuck Labs, Inc.|STTK - Company Value to Net Income|Future Price to Earnings Shattuck Labs|STTK - Price/Earnings to Growth Ratio|EV/EBITDA Multiple STTK|STTK - Operating profit EBITDA|Net earnings per share (EPS TTM) Shattuck Labs|STTK - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months shattucklabs.com|STTK - Expected net earnings per share growth this year|Expected earnings per share growth for next year Shattuck Labs, Inc.
- company sales and revenue statistics:
General company analysis:Shattuck Therapeutics (STTK)
Forward P/S measures an asset's market value relative to expected revenue, determining whether a business is overvalued or undervalued. The price-to-sales forward multiple reflects the valuation's sensitivity to license fee forecasts for Shattuck Labs, Inc. (STTK), where an increase in the indicator signals that the market is pricing in the success of clinical trials for solid tumor and lymphoma therapies.
Competitors of Shattuck Labs, Inc.
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio ADMA Corp ADMA|PTGX: Forward P/S Multiple|immunovant.com - Forward Price to Sales|KNSA (Kiniksa) - Forward P/S Multiple|Forward P/S Multiple Grifols SA|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|Price to Expected Revenue Ratio CLDX|Aurinia Pharmaceuticals - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BCRX (biocryst.com)|VERA: Forward Price-to-Revenue Multiple|DNTH - Forward P/S Multiple|PHVS: Forward P/S Multiple|Forward Price-to-Revenue Multiple AbCellera Corp|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|Forward P/S Multiple precigen.com|Forward Price-to-Revenue Multiple PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|Zenas Corp - Price-to-Projected Revenue Ratio|Immunome, Inc. - Forward P/S Multiple|GOSS - Forward P/S Multiple|KALV: Forward P/S Multiple|SEPN (Septerna, Inc.) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Savara Pharma (SVRA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple RIGL (Rigel Pharmaceuticals)|ANAB (anaptysbio.com) - Forward Price to Sales|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|Market Cap to Expected Sales Ratio enGene Holdings Inc (ENGN)|RAPT - Price-to-Projected Revenue Ratio|JBIO (Aerovate Therapeutics Inc) - Market Cap to Projected Revenue|ACRS: Forward P/S Multiple|Forward Price-to-Revenue Multiple kyvernatx.com|Forward Price-to-Revenue Multiple TLSA|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Market Cap to Expected Sales Ratio Theratechnologies, Inc|Avalo Therapeutics, Inc - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ELDN (eledon.com)|AGEN: Forward Price-to-Revenue Multiple|Climb Bio Inc. - Price to Expected Revenue Ratio|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Adagene Inc|Ikena Oncology, Inc. - Future Price to Revenue|Forward P/S Multiple EQ|CNTB (connectbiopharm.com) - Forward Price to Sales|Forward P/S Multiple IMUX (Immunic)|Forward P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Projected Revenue Ratio|Forward Price to Sales XFOR (x4pharma.com)|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Celularity|INMB (INmune Bio Corp) - Forward P/S Multiple|Forward P/S Multiple Barinthus Biotherapeutics Corp|Forward Price-to-Revenue Multiple KZR (Kezar Life Sciences)|SABS (sabbiotherapeutics.com) - Forward Price to Sales|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Market Cap to Expected Sales Ratio Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Projected Revenue Ratio|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ibioinc.com|Forward Price-to-Revenue Multiple CARM|Forward P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Market Cap to Projected Revenue|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. (AIM) - Market Cap to Future Revenue Ratio|ADTX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio GRI Bio Inc GRI|XRTX: Forward P/S Multiple|Vyome Therapeutics - Forward Price to Sales|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward P/S Multiple indaptusrx.com|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Price to Expected Revenue Ratio CALI|Affimed N.V. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ALLK (Allakos Inc)|HOOK: Forward Price-to-Revenue Multiple|IGMS - Forward P/S Multiple|ITOS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Ocean Biomedical Inc|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple Third Harmonic Bio Inc
